95. Autoimmune hepatitis Clinical trials / Disease details


Clinical trials : 52 Drugs : 68 - (DrugBank : 28) / Drug target genes : 19 - Drug target pathways : 112

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-003990-23-DE
(EUCTR)
21/06/202117/02/2021A Study to Investigate the Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Patients With Autoimmune HepatitisA DOUBLE-BLIND, RANDOMIZED,PARALLEL-GROUP, PHASE 2 STUDY TO INVESTIGATE THE EFFECT OF RO7049665 ON THE TIME TO RELAPSE FOLLOWINGSTEROID TAPERING IN PATIENTS WITH AUTOIMMUNE HEPATITIS Autoimmune Hepatitis (AIH)
MedDRA version: 20.1;Level: PT;Classification code 10003827;Term: Autoimmune hepatitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: IgG IL2/RO7049665
Product Code: RO7049665
INN or Proposed INN: NA
Other descriptive name: RO7049665/IgG-IL2/ IgG-IL2ND2
F. Hoffmann-La Roche LtdNULLNot RecruitingFemale: yes
Male: yes
84Phase 2Portugal;Canada;Australia;Netherlands;Germany;United Kingdom;Italy;New Zealand;Korea, Republic of
2EUCTR2020-003990-23-PT
(EUCTR)
18/06/202112/03/2021A Study to Investigate the Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Patients With Autoimmune HepatitisA DOUBLE-BLIND, RANDOMIZED,PARALLEL-GROUP, PHASE 2 STUDY TO INVESTIGATE THE EFFECT OF RO7049665 ON THE TIME TO RELAPSE FOLLOWINGSTEROID TAPERING IN PATIENTS WITH AUTOIMMUNE HEPATITIS Autoimmune Hepatitis (AIH)
MedDRA version: 20.1;Level: PT;Classification code 10003827;Term: Autoimmune hepatitis;System Organ Class: 10019805 - Hepatobiliary disorders
Product Name: IgG IL2/RO7049665
Product Code: RO7049665
INN or Proposed INN: NA
Other descriptive name: RO7049665/IgG-IL2/ IgG-IL2ND2
F. Hoffmann-La Roche LtdNULLNot RecruitingFemale: yes
Male: yes
84Phase 2Portugal;Canada;Australia;Netherlands;Germany;United Kingdom;Italy;New Zealand;Korea, Republic of
3EUCTR2020-003990-23-NL
(EUCTR)
28/04/202122/02/2021A Study to Investigate the Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Patients With Autoimmune HepatitisA DOUBLE-BLIND, RANDOMIZED,PARALLEL-GROUP, PHASE 2 STUDY TO INVESTIGATE THE EFFECT OF RO7049665 ON THE TIME TO RELAPSE FOLLOWINGSTEROID TAPERING IN PATIENTS WITH AUTOIMMUNE HEPATITIS Autoimmune Hepatitis (AIH)
MedDRA version: 20.1;Level: PT;Classification code 10003827;Term: Autoimmune hepatitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: IgG IL2/RO7049665
Product Code: RO7049665
INN or Proposed INN: NA
Other descriptive name: RO7049665/IgG-IL2/ IgG-IL2ND2
F. Hoffmann-La Roche LtdNULLNot RecruitingFemale: yes
Male: yes
84Phase 2Portugal;Canada;Australia;Germany;Netherlands;United Kingdom;Italy;New Zealand;Korea, Republic of
4EUCTR2020-003990-23-IT
(EUCTR)
11/03/202120/05/2021A Study to Investigate the Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Patients With Autoimmune HepatitisA DOUBLE-BLIND, RANDOMIZED,PARALLEL-GROUP, PHASE 2 STUDY TO INVESTIGATE THE EFFECT OF RO7049665 ON THE TIME TO RELAPSE FOLLOWING STEROID TAPERING IN PATIENTS WITH AUTOIMMUNE HEPATITIS - - Autoimmune Hepatitis (AIH)
MedDRA version: 20.1;Level: PT;Classification code 10003827;Term: Autoimmune hepatitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: IgG IL2/RO7049665
Product Code: [RO7049665]
Other descriptive name: RO7049665/IgG-IL2/ IgG-IL2ND2
F. HOFFMANN - LA ROCHE LTD.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
84Phase 2New Zealand;Italy;Korea, Republic of;Portugal;Canada;Korea, Democratic People's Republic of;Australia;Netherlands;Germany;United Kingdom
5NCT01988506
(ClinicalTrials.gov)
January 6, 20147/11/2013Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory DiseasesInduction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic ApproachRheumatoid Arthritis;Ankylosing Spondylitis;Systemic Lupus Erythematosus;Psoriasis;Behcet's Disease;Wegener's Granulomatosis;Takayasu's Disease;Crohn's Disease;Ulcerative Colitis;Autoimmune Hepatitis;Sclerosing Cholangitis;Gougerot-sjögren;Idiopathic Thrombocytopenic Purpura;Systemic SclerosisDrug: Interleukin 2Assistance Publique - Hôpitaux de ParisIltoo PharmaCompleted18 YearsN/AAll81Phase 2France